

EXHIBIT B



RECOMBITEK® Equine West Nile Virus vaccine. Works fast. Lasts long.



RECOMBITEK® Equine West Nile Virus (WNV) vaccine uses a brilliant bit of technology to stimulate fast and lasting immunity¹ against this widespread, virulent and devastating infectious disease.

RECOMBITEK Equine WNV vaccine delivers targeted WNV protection.

- Made using Merial recombinant canarypox-vectored technology
- Contains only the specific WNV antigens (M and E) needed to stimulate immunity
- Demonstrates both humoral and cell-mediated immune responses^{1,2}
- Does not replicate or revert to virulence in the horse


Proven against West Nile virus.

Onset of immunity in just 26 days after initial dose³


- Horses receiving a single dose of RECOMBITEK Equine WNV and unvaccinated controls were challenged via bites from WNV-infected mosquitoes
- 89% of vaccinated horses were protected from viremia
- 33% of vaccinates had no neutralizing antibodies present, but were protected, indicating strong, specific priming of cell-mediated immunity
- 11% of vaccinates developed a transient viremia
- Viremia was detected in 80% of controls 72 to 120 hours post-challenge, confirming severity of challenge

Proven 345-day duration of immunity⁴

- Vaccinates and controls were challenged via bites from WNV-infected mosquitoes
- 90% of vaccinated horses were protected from viremia
- Viremia was detected in 84% of controls 24 to 72 hours post-challenge, confirming severity of challenge




*8 of 10 control horses had detectable viremia 72 to 120 hours after challenge by WNV-infected mosquitoes.



*5 of 6 control horses had detectable viremia 24 to 72 hours after challenge by WNV-infected mosquitoes.


Anamnestic response that measured both antibody and CMI²

- Proven rapid antibody and cell-mediated immune (CMI) responses
- Lasting anamnestic response that includes both antibodies and CMI — including CMI presence throughout study
- Proven continued ability of horses to respond to canarypox-vectored West Nile Virus vaccine after repeated injections
- Non-antigen-specific cells secreted IFN- γ suggesting an immune stimulation from the canarypox vector alone



Revaccinate previously vaccinated horses with confidence.

- A single dose of RECOMBITEK Equine WNV vaccine stimulated an excellent anamnestic, virus-neutralizing immune response in horses previously vaccinated with West Nile-INNOVATORSM
- The mean antibody titer on Day 14 compared with Day 0 was significantly higher for horses vaccinated with RECOMBITEK Equine WNV vaccine ($P=0.02$), but was not significantly higher for horses revaccinated with a single dose of a killed vaccine.⁵



EXCELLENCE IN EQUINE HEALTH

RECOMBITEK uses canarypox-vectored vaccine technology for fast-acting, long-lasting protection against WNV.




Why protect horses with RECOMBITEK WNV?

- ♦ Full protection 14 days after primary two-dose series (only needed for naïve horses)¹
- ♦ Protection proven to last throughout the mosquito season¹
- ♦ Stimulates both humoral and cell-mediated immunity, putting both arms of the immune system into action^{1,2}
- ♦ Safe for use in foals 2 to 4 months of age and older³
- ♦ From Merial, a trusted leader in vaccine innovation and a maker of reliable equine vaccines, including IMRAB® for rabies

When to protect horses with RECOMBITEK Equine WNV vaccine.*

| Foal | Yearling | Performance | Pleasure | Broodmare |
|-----------------------------------|----------|-------------|----------|-----------|
| 1st dose: 2 to 4 months, or older | Annual* | Annual* | Annual* | Annual* |

*For horses that have received a primary two-dose series.



¹Siger L, et al. Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses. *American Journal of Veterinary Research* 2004;65(11):1459-1462.

²El Garch H, Minke J, et al. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse. *Vet Immunol Immunopathol* 2008;(123):230-239.

³Data on file at Merial. Study 02-092.

⁴Groenbaugh DA, et al. The anamnestic serologic response to vaccination with a canarypox virus-vectored recombinant West Nile Virus (WNV) vaccine in horses previously vaccinated with an inactivated WNV vaccine. *Vet Ther* 2004;5(4):251-257.

⁵USDA-approved label claim.

RECOMBITEK, IMRAB, ZIMECTERIN and EQUIOXX are registered trademarks, and POTOMAVAC and the HORSE HEAD LOGO are trademarks, of Merial.

GASTROGARD and ULCERGARD are registered trademarks of the AstraZeneca Group of Companies. West Nile-INNOVATOR is a registered trademark of Wyeth.

©2008 Merial Limited, Duluth, GA. All rights reserved. LAGEBWB01R (8/08)



1-888-MERIAL-1

Merial Family of Brands

